French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Good morning, and welcome to the Agios Pharmaceuticals Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now ...

Fintel reports that on November 20, 2025, Goldman Sachs maintained coverage of Agios Pharmaceuticals (NasdaqGS:AGIO) with a Neutral recommendation. Analyst Price Forecast Suggests 125.55% Upside As of ...

Goldman Sachs lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $25 from $40 and keeps a Neutral rating on the shares. Shares fell sharply after Phase 3 RISE UP results showed strong ...

Get the detailed quarterly/annual income statement for Agios Pharmaceuticals, Inc. (AGIO). Find out the revenue, expenses and profit or loss over the last fiscal year.

Understand the cash flow statement for Agios Pharmaceuticals, Inc. (AGIO), learn where the money comes from and how the company spends it.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular ...

Agios Pharmaceuticals reports mixed Phase 3 results for its sickle cell disease drug, mitapivat, showing promise but missing a key secondary goal. Agios Pharmaceuticals has unveiled mixed topline ...